Didem SOYDEMİR, Çağatay GÜNAY, Irmak GÜZEL, Arzu SAYINER, Sema HIZ, Uluç YİŞ, Gamze SARIKAYA UZAN

Asemptomatik SARS-CoV-2 pozitif spinal müsküler atrofi tip 1 olgusu

Coronavirus hastalığı 2019 (COVID 19), Coronavirus-2 (SARS CoV 2)’den kaynaklanan ciddi akut respiratuar sendrom ile sonuçlanan halen dünya çapında görülen pandemi ve halk sağlığı acilidir. Altta yatan kronik solunum sistemi hastalığına sahip bireylerde daha ağır geçirildiği bilinen COVID19, SMA hastalıklı bireylerde ciddi komplikasyonlara yol açabilir. Bununla birlikte COVID 19’un SMA hastalarındaki seyri ve nusinersen tedavisi üzerine etkisi ile ilgili bir literatür ya da vaka sunumu henüz bildirilmemiştir. Amacımız aile içi bireyleri SARS CoV 2 polymerase chain reaction (PCR) negatif iken kendisi pozitif olan asemptomatik SARS CoV 2 taşıyıcısı SMA Tip 1 tanılı nusinersen tedavisi verdiğimiz 3,5 aylık bir kız olguyu sunarak gelecekte de dünya genelinde etkisini sürdüreceğini düşündüğümüz SARSCoV 2 pozitif SMA hastalarının yönetimi ile ilgili literatüre katkıda bulunmaktır.

AN ASYMPTOMATIC CASE OF SARS-COV-2 POSITIVE SPINAL MUSCULAR ATROPHY TYPE 1

Coronavirus disease 2019 (COVID-19) is a worldwide pandemia and public health emergency resulting from Coronavirus-2 (SARS-CoV-2) which results in severe acute respiratory syndrome. Coronavirus disease 2019, known to be drastically experienced in those with underlying chronic respiratory system diseases, can lead to serious complications in individuals with spinal muscular atrophy (SMA) disease. Nevertheless, there has been no case report or literature publication regarding the course of COVID 19 in SMA patients and its effect on nusinersen treatment yet. The aim of this study is to contribute to the literature concerning the management of SARS-CoV-2 positive SMA patients. We present a 3.5 month-old baby girl whose SARS-CoV-2 polymerase chain reaction (PCR) was positive while it was negative in other family members, she was diagnosed as asymptomatic SARS-CoV-2 carrier and nusinersen treatment was administered.

PDF

___

1. Ludwig S, Zarbock A. Coronaviruses and SARS CoV 2: a brief overview. Anesth Analg. 2020;131(1):93 6.
2. Zheng Y, Xu H, Yang M, Zenga Y, Chena H, Liu R, et al. Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID 19 in Chengdu. J Clin Virol. 2020;127:104366.
3. Du W, Yu J, Wang H, Zhang X, Zhang S, Li Q, et al. Clinical characteristics of COVID 19 in children compared with adults in Shandong Province, China. Infection. 2020;48(3):445 52.
4. Samaha FJ, Buncher CR, Russman BS, White ML, Iannaccone ST, Barker L, et al. Pulmonary Function in Spinal Muscular Atrophy. J of Child Neurol. 1994;9:326 9.
5. Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 2010;24(15):1634 44.
6. Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile onset spinal muscular atrophy with nusinersen: a phase 2, openlabel, dose escalation study. Lancet 2016;388(10063):3017 26.
7. Veerapandiyan A, Connolly AM, Finkel RS, Arya K, Mathews KD, Smith EC, et al. Spinal muscular atrophy care in the COVID 19 pandemic era. Muscle & Nerve. 2020;62(1):46 9.
8. Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile onset spinal muscular atrophy. N Engl J Med. 2017;377:1723 32.
9. Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM et al. Nusinersen versus sham control in later onset spinal muscular atrophy. N Engl J Med. 2018;378:625 35.
10. Poli P, Goffredo M, Padoan R, Badolato R. Asymptomatic case of Covid 19 in an infant with cystic fibrosis. J Cyst Fibros. 2020;19(3):e18.
11. Cai J, Xu J, Lin D, Zhi Y, Lei X, Zhenghai Q, et al. A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features, Clin Infect Dis. 2020;71(6):1547 51.